The PD-L1 inhibitor avelumab—approved by the FDA in March for the treatment of Merkel cell carcinoma—demonstrated a high number of durable responses in an international, open-label, prospective phase II study. The results of the study, which supported the FDA's decision, were presented in April at the American Association for Cancer Research (AACR) Annual Meeting 2017.
http://ift.tt/2qN3G9A
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου